Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis

World Journal of Gastroenterology

Volumn 21, Issue 25, 2015, Pages 7895-7906

  Pang, Qing ^a   Qu, Kai ^a   Bi, Jian Bin ^a   Liu, Su Shun ^a   Zhang, Jing Yao ^a   Song, Si Dong ^a   Lin, Ting ^a   Xu, Xin Sen ^a   Wan, Yong ^a   Tai, Ming Hui ^a   Liu, Hao Chen ^a   Dong, Ya Feng ^b   Liu, Chang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Blood platelets; Hepatocellular carcinoma; Prognosis; Recurrence; Thrombocytopenia

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; DISEASE ASSOCIATION; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; PREDICTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER NEOPLASMS; ODDS RATIO; PATHOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84936745028     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i25.7895     Document Type: Article

References (54)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736 (11) 61347-0]
2. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010;58:273-277 [PMID: 20378277 DOI: 10.1016/j.patbio.2010.01.005]
3. Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol 2013;59:897-903 [PMID: 23714157 DOI: 10.1016/j.jhep. 2013.05.031]
4. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer =2 cm: results from two Western centers. Hepatology 2013;57:1426-1435 [PMID: 22576353 DOI: 10.1002/hep. 25832]
5. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844-855 [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627]
6. Kondo R, Yano H, Nakashima O, Tanikawa K, Nomura Y, Kage M. Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C. J Gastroenterol 2013;48:526-534 [PMID: 22911171 DOI: 10.1007/s00535-012-0656-2]
7. Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, Fleischmann E, Gruenberger B, Brostjan C, Gruenberger T. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology 2014;60:257-266 [PMID: 24277679 DOI: 10.1002/hep. 26950]
8. Udell JA, Wang CS, Tinmouth J, Fitz Gerald JM, Ayas NT, Simel DL, Schulzer M, Mak E, Yoshida EM. Does this patient with liver disease have cirrhosis? JAMA 2012;307:832-842 [PMID: 22357834 DOI: 10.1001/jama.2012.186]
9. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46:912-921 [PMID: 17705266 DOI: 10.1002/hep. 21835]
10. Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:10108-10114 [PMID: 25110437 DOI: 10.3748/wjg.v20. i29.10108]
11. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN. Hepatocellular carcinoma surveillance at 4-vs.12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol 2013;108:416-424 [PMID: 23318478 DOI: 10.1038/ajg.2012.445]
12. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012;56:2134-2141 [PMID: 22806754 DOI: 10.1002/hep. 25949]
13. Yang T, Zhang J, Lu JH, Yang GS, Wu MC, Yu WF. Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg 2011;35:2073-2082 [PMID: 21656309 DOI: 10.1007/s00268-011-1161-0]
14. Pang Q, Zhang JY, Song SD, Qu K, Xu XS, Liu SS, Tai MH, Liu HC, Liu C. Thrombocytopenia as an inexpensive, valuable predictor for survival in patients with hepatocellular carcinoma. Scand J Gastroenterol 2014;49:1507-1508 [PMID: 25275671 DOI: 10.3109/00365521.2014.962076]
15. Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, Liang LJ, Guo P, Hao Y, Peng BG. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol 2014;21:3802-3809 [PMID: 24849520 DOI: 10.1245/s10434-014-3771-x]
16. Pang Q, Zhang JY, Xu XS, Song SD, Qu K, Chen W, Zhou YY, Miao RC, Liu SS, Dong YF, Liu C. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence. World J Gastroenterol 2015;21; 5607-5621 [PMID: 25987786 DOI: 10.3748/wjg.v21.i18.5607]
17. Oxford Centre for Evidence-based Medicine. Critical appraisal. Accessed 2015 Feb. 28. Available from: URL: http://www.cebm.net
18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012 [PMID: 10789670]
19. Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon AH. Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg 2013;37:820-828 [PMID: 23340708 DOI: 10.1007/s00268-013-1902-3]
20. Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C. Cancer Epidemiol Biomarkers Prev 2011;20:2204-2211 [PMID: 21876190 DOI: 10.1158/1055-9965. EPI-11-0464]
21. Amano H, Tashiro H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Itamoto T, Asahara T, Ohdan H. Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria. J Gastrointest Surg 2011;15:1173-1181 [PMID: 21512850 DOI: 10.1007/s11605-011-1538-2]
22. Nonaka K, Fujioka H, Takii Y, Abiru S, Migita K, Ito M, Kanematsu T, Ishibashi H. mPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC. World J Gastroenterol 2010;16:4846-4853 [PMID: 20939114 DOI: 10.3748/wjg.v16.i38.4846]
23. Kang CM, Choi GH, Kim DH, Choi SB, Kim KS, Choi JS, Lee WJ. Revisiting the role of nonanatomic resection of small (& lt; or = 4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function. J Surg Res 2010;160:81-89 [PMID: 19577249 DOI: 10.1016/j.jss.2009.01.021]
24. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569-577; quiz 578 [PMID: 22158026 DOI: 10.1038/ajg.2011.425]
25. Nishikawa H, Osaki Y, Kita R, Kimura T, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 2012;41:903-909 [PMID: 22692851 DOI: 10.3892/ijo.2012.1512]
26. Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol 2012;46:62-70 [PMID: 21934530 DOI: 10.1097/MCG.0b013e31822b36cc]
27. Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, Ikeda H, Araki Y, Sakaguchi K, Shiratori Y. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol 2008;23:453-458 [PMID: 17725599 DOI: 10.1111/j.1440-1746.2007.05120.x]
28. Fuke H, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Yoneda K, Yamamoto N, Ito K, Takaki H, Nakatsuka A, Yamakado K, Takeda K, Takei Y. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. Aliment Pharmacol Ther 2008;27:1253-1260 [PMID: 18221404 DOI: 10.1111/j.1365-2036.2008.03627.x]
29. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006;44:1518-1527 [PMID: 17133456]
30. Yamanaka Y, Shiraki K, Miyashita K, Inoue T, Kawakita T, Yamaguchi Y, Saitou Y, Yamamoto N, Nakano T, Nakatsuka A, Yamakado K, Takeda K. Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C. World J Gastroenterol 2005;11:2174-2178 [PMID: 15810088]
31. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T. Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer 2011;117:4018-4025 [PMID: 21365625 DOI: 10.1002/cncr.25989]
32. Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Kanda T, Miyazaki M, Yokosuka O. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci 2014;11:707-712 [PMID: 24843320 DOI: 10.7150/ijms.8764]
33. Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2012;57:1092-1101 [PMID: 21989822 DOI: 10.1007/s10620-011-1934-1]
34. Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011;16:210-220 [PMID: 21152943 DOI: 10.1007/s10147-010-0150-x]
35. Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007;13:5343-5350 [PMID: 17879404]
36. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232 [PMID: 10915728 DOI: 10.1053/jhep. 2000.9409]
37. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 2012;130:2747-2760 [PMID: 22261860 DOI: 10.1002/ijc.27441]
38. Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Ogawa M, Sakabe K, Yamazaki K, Hirohashi K. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res 2004;30:221-225 [PMID: 15589130 DOI: 10.1016/j.hepres. 2004.10.005]
39. Karasu Z, Tekin F, Ersoz G, Gunsar F, Batur Y, Ilter T, Akarca US. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci 2007;52:1535-1539 [PMID: 17464564 DOI: 10.1007/s10620-006-9144-y]
40. Carr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology 2013;85:153-159 [PMID: 23988857 DOI: 10.1159/000354416]
41. Taketomi A, Kitagawa D, Itoh S, Harimoto N, Yamashita Y, Gion T, Shirabe K, Shimada M, Maehara Y. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. J Am Coll Surg 2007;204:580-587 [PMID: 17382216 DOI: 10.1016/j.jamcollsurg.2007.01.035]
42. Maithel SK, Kneuertz PJ, Kooby DA, Scoggins CR, Weber SM, Martin RC, McMasters KM, Cho CS, Winslow ER, Wood WC, Staley CA. Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg 2011;212:638-648; discussion 648-650 [PMID: 21463803 DOI: 10.1016/j.jamcollsurg. 2011.01.004]
43. Lee HS, Park SY, Kim SK, Kweon YO, Tak WY, Cho CM, Jeon SW, Jung MK, Park HG, Lee DW, Choi SY. Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma. Clin Mol Hepatol 2012;18:302-308 [PMID: 23091811 DOI: 10.3350/cmh.2012.18.3.302]
44. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M, Nakatani T. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006;41:1214-1219 [PMID: 17287901 DOI: 10.1007/s00535-006-1950-7]
45. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007;22:669-675 [PMID: 17444854 DOI: 10.1111/j.1440-1746.2007.04898.x]
46. Kobeisy MA, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol 2012;13:49-53 [PMID: 22980591 DOI: 10.1016/j.ajg.2012.06.004]
47. Nozaki R, Murata S, Nowatari T, Maruyama T, Ikeda N, Kawasaki T, Fukunaga K, Ohkohchi N. Effects of thrombopoietin on growth of hepatocellular carcinoma: Is thrombopoietin therapy for liver disease safe or not? Hepatol Res 2013;43:610-620 [PMID: 23157389 DOI: 10.1111/hepr.12006]
48. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007;6:1932-1941 [PMID: 17604334 DOI: 10.1158/1535-7163. MCT-06-0720]
49. Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013;58:1790-1796 [PMID: 23314854 DOI: 10.1007/s10620-012-2527-3]
50. Hu C, Chen R, Chen W, Pang W, Xue X, Zhu G, Shen X. Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer. Exp Ther Med 2014;8:125-132 [PMID: 24944610 DOI: 10.3892/etm.2014.1699]
51. Sarpel U, Ayo D, Lobach I, Xu R, Newman E. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford) 2012;14:741-745 [PMID: 23043662 DOI: 10.1111/j.1477-2574.2012.00507.x]
52. Carr BI, Cavallini A, D'Alessandro R, Refolo MG, Lippolis C, Mazzocca A, Messa C. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 2014;14:43 [PMID: 24468103 DOI: 10.1186/1471-2407-14-43]
53. Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Narayanan Menon KV, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant 2013;27:555-561 [PMID: 23758296 DOI: 10.1111/ctr.12150]
54. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-465 [PMID: 16557381 DOI: 10.1007/s00432-006-0091-y]